JP2013535957A - 所望の薬学的及び栄養学的脂肪酸を取得する方法 - Google Patents
所望の薬学的及び栄養学的脂肪酸を取得する方法 Download PDFInfo
- Publication number
- JP2013535957A JP2013535957A JP2013515932A JP2013515932A JP2013535957A JP 2013535957 A JP2013535957 A JP 2013535957A JP 2013515932 A JP2013515932 A JP 2013515932A JP 2013515932 A JP2013515932 A JP 2013515932A JP 2013535957 A JP2013535957 A JP 2013535957A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- culture
- incubator
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 88
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 26
- 239000000194 fatty acid Substances 0.000 title claims abstract description 26
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 26
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 26
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 92
- 239000002028 Biomass Substances 0.000 claims abstract description 27
- 230000000243 photosynthetic effect Effects 0.000 claims abstract description 17
- 230000029553 photosynthesis Effects 0.000 claims abstract description 7
- 238000010672 photosynthesis Methods 0.000 claims abstract description 7
- 239000007789 gas Substances 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 44
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 238000000605 extraction Methods 0.000 claims description 24
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 22
- 230000008569 process Effects 0.000 claims description 21
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 238000000926 separation method Methods 0.000 claims description 17
- 239000000651 prodrug Substances 0.000 claims description 16
- 229940002612 prodrug Drugs 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 241000195493 Cryptophyta Species 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 239000004568 cement Substances 0.000 claims description 5
- 239000002535 acidifier Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000012298 atmosphere Substances 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 238000010908 decantation Methods 0.000 claims description 4
- 238000002203 pretreatment Methods 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000001079 digestive effect Effects 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 241000196319 Chlorophyceae Species 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 241000199914 Dinophyceae Species 0.000 claims description 2
- 241000195633 Dunaliella salina Species 0.000 claims description 2
- 206010022562 Intermittent claudication Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 238000005377 adsorption chromatography Methods 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 208000025307 bipolar depression Diseases 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000009297 electrocoagulation Methods 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 2
- 241000196307 prasinophytes Species 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims 3
- 239000003960 organic solvent Substances 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 241000196321 Tetraselmis Species 0.000 claims 2
- 208000015606 cardiovascular system disease Diseases 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 238000010979 pH adjustment Methods 0.000 claims 2
- 241001518925 Raphidophyceae Species 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 124
- 229910002092 carbon dioxide Inorganic materials 0.000 description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 24
- 235000021323 fish oil Nutrition 0.000 description 17
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 229940012843 omega-3 fatty acid Drugs 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 235000019688 fish Nutrition 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 235000021354 omega 7 monounsaturated fatty acids Nutrition 0.000 description 11
- 241000251468 Actinopterygii Species 0.000 description 10
- 239000005431 greenhouse gas Substances 0.000 description 10
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 10
- 239000006014 omega-3 oil Substances 0.000 description 10
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- -1 carboxy, carbonyl Chemical group 0.000 description 8
- 238000011109 contamination Methods 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 7
- 229910052753 mercury Inorganic materials 0.000 description 7
- 235000019645 odor Nutrition 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000004626 essential fatty acids Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 240000000950 Hippophae rhamnoides Species 0.000 description 4
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 240000002791 Brassica napus Species 0.000 description 3
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000021319 Palmitoleic acid Nutrition 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 3
- 235000012716 cod liver oil Nutrition 0.000 description 3
- 239000003026 cod liver oil Substances 0.000 description 3
- 238000002485 combustion reaction Methods 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940013317 fish oils Drugs 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000012780 transparent material Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000219198 Brassica Species 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- WDZCJFZKULYAMW-UHFFFAOYSA-N [O-][N+](S)=O Chemical compound [O-][N+](S)=O WDZCJFZKULYAMW-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 150000001356 alkyl thiols Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012223 aqueous fraction Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 150000002013 dioxins Chemical class 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000199 molecular distillation Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000919496 Erysimum Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241001274189 Pomatomus saltatrix Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000405713 Tetraselmis suecica Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 241000269959 Xiphias gladius Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000561 aggregant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical group OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000567 combustion gas Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000021084 monounsaturated fats Nutrition 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000000258 photobiological effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 150000003071 polychlorinated biphenyls Chemical class 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009774 resonance method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000021148 salty food Nutrition 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000021335 sword fish Nutrition 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6432—Eicosapentaenoic acids [EPA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6434—Docosahexenoic acids [DHA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6463—Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
・抗炎症作用:オメガ‐7は、皮膚炎、湿疹及び乾癬等の皮膚の症状、並びに胃及び消化性潰瘍等の粘膜の症状を緩和又は改善し、特に女性器の炎症に作用する。
・温和な抗炎症剤:オメガ‐7は、皮膚及び粘膜の状態により起こる痛みに作用する。
・抗酸化剤:オメガ‐7は、フリーラジカル等の物質から組織を保護する。
・栄養:オメガ‐7は、皮膚及び粘膜の栄養となる。
・オレイン酸(18:1 ω‐9)。オリーブ油及び他のモノ不飽和脂肪の主要な成分である。
・エルカ酸(22:1 ω‐9)。菜種 (Brassica napus)、アラセイトウ(Erysimum)種子及びマスタード (Brassica)種子に見られる。高度にエルカ酸を含有する菜種は、通常、乾燥剤及び保護剤として、画材及び塗料に使用される。
a)CO2を含有するガス又は複数のガスの混合物を、1種類以上の光合成微小藻類を含有する培養器に導入する工程;
b)導入されたCO2を使用して当該微小藻類が光合成を行い、式(I)
A及びXは独立して同一又は相違し、アルキルC3−C10, アルケニルC1−C10, シクロアルキルC1−C7、又は置換された、若しくは置換されていないアリール基から選択され:
nは1〜10のいずれかの整数であり;
Rは、H、ヒドロキシ基、アルキルC1−C4, アルケニルC1−C3, シクロアルキルC3−C7、又は置換された、若しくは置換されていないアリール基から選択され;
Wは、ヒドロキシ基、1つの追加の式(I)の化合物が結合しているためジグリセリドを形成するグリセロール分子、又は2つの追加の式(I)の化合物が結合しているためトリグリセリドを形成するグリセロール分子からなる群から選択される]
の化合物並びにその塩、医薬として許容される塩、溶媒和物、及びそのプロドラッグを含有するバイオマスが生産される工程;
c)工程b)で取得されたバイオマスから式(I)の化合物を抽出する工程;及び
d)工程c)で取得された抽出物から式(I)の化合物を濃縮及び/又は精製する工程;
を含み、光合成工程の後、培養物の5〜100%が培養器から取り出され、当該回収物からバイオマスを含有する固体分画が分離され、続いて当該分画から式(I)の化合物が抽出され、そして、炭酸塩及び/又は重炭酸塩を含有する液体分画から炭酸塩及び/又は重炭酸塩が分離され、続いて炭酸塩及び/又は重炭酸塩が除去された当該液体分画の少なくとも一部を、前記培養器に戻すことを特徴とする、所望の薬学的又は栄養学的脂肪酸を取得する方法に関する。
CO2を含有するガス又はガスの混合物を導入する工程;
微小藻類によりCO2の同化及び変換がなされ、式(I)の化合物を含有するバイオマスが生産される工程;
培養培地を機械的に処理する工程;
水相を機械的−化学的に処理する工程;
式(I)の化合物を抽出する工程;及び
式(I)の化合物を濃縮及び/又は精製する工程;
を有する。
好ましい態様において、温室効果ガス等のCO2を含有するガス又はガスの混合物を導入する工程は、内部から、及び/又は外部から、そのようなガス又はガスの混合物を、一種類以上の光合成微小藻類が入った光合成型培養器内に供給する工程を含む。
他の好ましい態様において、CO2を同化及び変換する工程は、微小藻類の光合成機能による光合成プロセスを含み、当該プロセス中、培養器には、自然光、人工光、又はそれらの任意の組み合わせが継続的に照射される。
他の好ましい態様において、培養培地を機械的に処理する工程は、以下の小工程:
培養器から培養物を取り出す、又は少なくとも部分的に取り出す工程;
取り出された培養物を、バイオマスを含有する固体分画及び炭酸塩及び/又は重炭酸塩を含有する液体分画に分離する工程;
を含む。
他の好ましい態様において、水相を化学的に処理する工程は、以下の小工程:
炭酸塩及び/又は重炭酸塩の形態で溶解している、培養器から取り出された培養物の一部に由来する液体分画中に存在するCO2を、アルカリの添加により、対応する炭酸塩の沈殿に化学的に変換する工程;及び
溶解している炭酸塩及び/又は重炭酸塩を実質的に含有していない液相の少なくとも一部を培養器に再循環する工程;
を含む。
他の好ましい態様において、式(I)
イソプロパノール、ヘキサン、ヘプタン、メタノール、エタノール、ジクロロメタン、アセトン、水、クロロホルム、酢酸ブチル、テトラヒドロフラン、2−メチルテトラヒドロフラン、ブタノール、トルエン、ベンゼン又はこれらの任意の組み合わせからなる群から選択される溶媒による抽出;
超臨界条件、即ち圧力100〜300bar、好ましくは180〜220bar、温度25〜350℃、好ましくは40〜80℃で、CO2を溶媒として使用する抽出。
超音波処理:藻類が100〜1000Hz、好ましくは300〜400Hzの周波数で、1〜25分間、好ましくは2〜20分間処理される。
ホモジネーション又はキャビテーション:微小藻類が、1〜2500bar、好ましくは250〜1200barの圧力で処理される。この手順は、細胞が破壊されるまで数回繰り返されてもよい。通常繰り返しの回数は1〜5回、好ましくは1回である。
pHの変動による処理:藻類の破砕は、pHを9よりも高くする(無機又は有機性の弱塩基又は強塩基を用いる)、又は6よりも低くする(無機又は有機性の弱酸又は強酸を用いる)ことにより達成される。
他の好ましい態様において、式(I)の化合物を濃縮及び/又は精製する工程は、この目的に適した任意の方法により実施されるが、好ましくは、分子若しくは分割分離(fractioned distillation)、酵素分割、CO2を用いた超臨界抽出、低温での結晶化、吸着クロマトグラフィー、及び尿素を用いた沈殿からなる群から選択される技術の1つ以上を使用して実施される。精製は、所望の生産物の濃縮の結果として達成される。
A及びXは独立して同一又は相違し、アルキルC3−C10, アルケニルC1−C10, シクロアルキルC1−C7、又は置換された、若しくは置換されていないアリール基から選択され:
nは1〜10のいずれかの整数であり;
Rは、H、ヒドロキシ基、アルキルC1−C4, アルケニルC1−C3, シクロアルキルC3−C7、又は置換された、若しくは置換されていないアリール基から選択され;
Wは、ヒドロキシ基、1つの追加の式(I)の化合物が結合しているためジグリセリドを形成するグリセロール分子、又は2つの追加の式(I)の化合物が結合しているためトリグリセリドを形成するグリセロール分子からなる群から選択される]
を有し、その塩、医薬として許容される塩、溶媒和物、及びそのプロドラッグをも想定される。
Claims (36)
- 所望の薬学的又は栄養学的脂肪酸を取得する方法であって、以下の工程
a)CO2を含有するガス又は複数のガスの混合物を、1種類以上の光合成微小藻類を含有する培養器に導入する工程;
b)導入されたCO2を使用して当該微小藻類が光合成を行い、式(I)
A及びXは独立して同一又は相違し、アルキルC3−C10, アルケニルC1−C10, シクロアルキルC1−C7、又は置換された、若しくは置換されていないアリール基から選択され:
nは1〜10のいずれかの整数であり;
Rは、H、ヒドロキシ基、アルキルC1−C4, アルケニルC1−C3, シクロアルキルC3−C7、又は置換された、若しくは置換されていないアリール基から選択され;
Wは、ヒドロキシ基、1つの追加の式(I)の化合物が結合しているためジグリセリドを形成するグリセロール分子、又は2つの追加の式(I)の化合物が結合しているためトリグリセリドを形成するグリセロール分子からなる群から選択される]
の化合物並びにその塩、医薬として許容される塩、溶媒和物、及びそのプロドラッグを含有するバイオマスが生産される工程;
c)工程b)で取得されたバイオマスから式(I)の化合物を抽出する工程;及び
d)工程c)で取得された抽出物から式(I)の化合物を濃縮及び/又は精製する工程;
を含み、光合成工程の後、培養物の5〜100%が培養器から取り出され、当該回収物からバイオマスを含有する固体分画が分離され、続いて当該分画から式(I)の化合物が抽出され、そして、炭酸塩及び/又は重炭酸塩を含有する液体分画から炭酸塩及び/又は重炭酸塩が分離され、続いて炭酸塩及び/又は重炭酸塩が除去された当該液体分画の少なくとも一部を、前記培養器に戻すことを特徴とする、所望の薬学的又は栄養学的脂肪酸を取得する方法。 - 前記培養器から少なくとも一部の培養物を取り出す工程において、5〜50%の培養物が取り出される、請求項1に記載の方法。
- 前記培養器から少なくとも一部の培養物を取り出す工程において、10%の培養物が取り出される、請求項2に記載の方法。
- 前記工程a)の前に、CO2を含有するガス又は複数のガスの混合物が、SOx、NOx、及び水分の除去、並びに30〜40℃の温度調整を含む前処理に付される、請求項1〜3のいずれか1項に記載の方法。
- 前記微小藻類が、クロロフィケアエ(Clorophyceae)、バチリアリオフィケアス(Bacilliarioficeas)、ジノフィケアエ(Dinophyceae)、クリプトフィケアエ(Cryptophyceae)、クリソフィケアエ(Chrysophyceae)、ハプトフィケアエ(Haptophyceae)、プラシノフィケアエ(Prasinophyceae)、ラフィドフィケアエ(Raphidophyceae)、ユースティグマトフィケアエ(Eustigmatophyceae)、及びそれらの任意の組み合わせからなる群から選択される、請求項1〜4のいずれか1項に記載の方法。
- 前記微小藻類が、ドゥナリエラ・サリナ(Dunaliella salina)、テトラセルミス・ガルバナ(Tetraselmis Galvana)、テトラセルミス・スエキカ(Tetraselmis suecica)、イイソクリシス・ガルバナ(Iisochrysis galbana)、ナンノクロロプシス・ガディタナ(Nannochloropsis Gaditana)及びナンノクロリス(Nannochloris)、及びそれらの任意の組み合わせからなる群から選択される、請求項5に記載の方法。
- 前記工程a)において培養器に導入されるガス又は複数のガスの混合物が、外部からの大気若しくは産業排気、又は当該方法の過程で発生する内部からのガス、又はそれらの任意の組み合わせである、請求項1〜6のいずれか1項に記載の手順。
- 前記工程a)において培養器に導入されるガス又は複数のガスの混合物が、セメント工場から発生したものである、請求項7に記載の方法。
- 前記工程b)において、乱流培養が行われ、任意の組み合わせの天然及び/又は人工光に暴露される、請求項1〜8のいずれか1項に記載の脂肪酸取得方法。
- 前記反応容器から取り出された少なくとも一部の培養物のpHが3.5〜8に調整される、請求項1〜9のいずれか1項に記載の方法。
- 前記取り出された培養物のpHが6〜8に調整される、請求項10に記載の方法。
- 前記pHの調製が、CO2、CO2及び大気の混合物、強酸若しくは弱酸、又はそれらの任意の組み合わせから選択される酸性化剤を添加されることにより実施される、請求項10又は11のいずれか1項に記載の方法。
- 前記pH調整が、培養物にCO2及び大気の混合物を添加することにより実施される、請求項12に記載の方法。
- 前記培養器から少なくとも一部の培養物を取り出す工程の後、バイオマスを含有する固体分画と、炭酸塩及び/又は重炭酸塩を含有する液体分画との分離が、ろ過、遠心分離、凝集、電気凝固、超音波、蒸発、デカンテーション、又はそれらの任意の組み合わせからなる群から選択される1つ以上の技術により実施される、請求項1〜13のいずれか1項に記載の方法。
- 前記培養器から取り出した少なくとも一部の培養物から分離した液体分画の炭酸塩及び/又は重炭酸塩の分離が、1つ以上のアルカリの添加により引き起こされる対応する炭酸塩の沈殿により実施される、請求項1〜14のいずれか1項に記載の方法。
- 工程c)の前に、培養物に対し、藻類細胞を溶解する工程が適用される、請求項1〜15のいずれか1項に記載の方法。
- 前記溶解が、100〜1000Hzの周波数の超音波により実施される、請求項16に記載の方法。
- 前記溶解が、250〜1200barの圧力でのキャビテーションにより実施される、請求項16に記載の方法。
- 前記溶解が、酸又は塩基の添加によりpHを6未満又は9超にすることにより実施される、請求項16に記載の方法。
- 工程c)の前に請求項17〜19に記載の溶解手段のいずれか1つ以上が1〜5回繰り返される、請求項16に記載の方法。
- 工程c)において、有機溶媒による抽出、超臨界条件下での抽出、又はこれらの組み合わせからなる群から選択される技術により抽出が実施される、請求項1〜20のいずれか1項に記載の方法。
- 前記抽出が、有機溶媒を使用して実施される、請求項21に記載の方法。
- 前記有機溶媒が、ヘキサン:エタノールの2:1混合物である、請求項21に記載の方法。
- 前記工程d)が、分子若しくは分割分離(fractioned distillation)、酵素分割、CO2を用いた超臨界抽出、低温での結晶化、吸着クロマトグラフィー、尿素を用いた沈殿、又はこれらの任意の組み合わせからなる群から選択される技術により実施される、請求項1〜23のいずれか1項に記載の方法。
- 請求項1〜24のいずれか1項に記載の方法を使用して脂肪酸を取得するための、CO2を含むガスの使用。
- 前記ガスがセメント工場の排気である、請求項25に記載の使用。
- 前記ガスが、培養器に添加される前に、Sox、Nox及び水分の除去、及び30〜40℃の範囲の温度調整の1つ以上の前処理に付される、請求項25又は26のいずれかに記載の使用。
- 請求項1〜24のいずれか1項に記載の方法により取得される、式(I)
A及びXは独立して同一又は相違し、アルキルC3−C10, アルケニルC1−C10, シクロアルキルC1−C7、又は置換された、若しくは置換されていないアリール基から選択され:
nは1〜10のいずれかの整数であり;
Rは、H、ヒドロキシ基、アルキルC1−C4, アルケニルC1−C3, シクロアルキルC3−C7、又は置換された、若しくは置換されていないアリール基から選択され;
Wは、ヒドロキシ基、1つの追加の式(I)の化合物が結合しているためジグリセリドを形成するグリセロール分子、又は2つの追加の式(I)の化合物が結合しているためトリグリセリドを形成するグリセロール分子からなる群から選択される]
並びにその塩、医薬として許容される塩、溶媒和物、及びそのプロドラッグ。 - 請求項28に記載の式(I)の化合物であって:
A及びXは独立して同一又は相違し、アルキルC1−C8, アルケニルC1−C5及びシクロアルキルC4−C6から選択され:
Wは、OH、又は2つの追加の式(I)の化合物が結合しているためトリグリセリドを形成するグリセロール分子であり;
nは1〜7のいずれかの整数であり;
Rは、H、ヒドロキシ基、アルキルC1−C4及びシクロアルキルC4−C6から選択される;
請求項28に記載の式(I)の化合物。 - 心臓血管系、消化器系、神経系、又は免疫系の疾患を治療するための、請求項28〜30のいずれか1項に記載の化合物の薬物としての使用。
- 請求項28〜30のいずれか1項に記載の1つ以上の式(I)の化合物、その塩、溶媒和物又はプロドラッグ、及び1つ以上の医薬として許容される担体、助剤及び/又はビヒクルを含有する医薬組成物。
- 更に他の有効成分を含有する、請求項32に記載の医薬組成物。
- 請求項28〜30のいずれか1項に記載の化合物を含有する栄養補助剤。
- 心臓血管系、消化器系、神経系、又は免疫系疾患を予防及び/又は治療するための薬物の製造における、請求項28〜30のいずれか1項に記載の式(I)の化合物の使用。
- 糖尿病、クローン病、潰瘍性大腸炎、間欠性跛行、心臓血管疾患、嚢胞性線維症、双極性障害、鬱病、又は統合失調症を予防及び/又は治療する薬物の製造のための、請求項28〜30のいずれか1項に記載の式(I)の化合物の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2010/070424 WO2011161274A1 (es) | 2010-06-23 | 2010-06-23 | Procedimiento para la obtención de ácidos grasos de interés farmacológico y nutricional |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013535957A true JP2013535957A (ja) | 2013-09-19 |
JP5934704B2 JP5934704B2 (ja) | 2016-06-15 |
Family
ID=43902548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013515932A Expired - Fee Related JP5934704B2 (ja) | 2010-06-23 | 2010-06-23 | 所望の薬学的及び栄養学的脂肪酸を取得する方法 |
Country Status (20)
Country | Link |
---|---|
US (1) | US9573875B2 (ja) |
EP (1) | EP2586869B1 (ja) |
JP (1) | JP5934704B2 (ja) |
CN (1) | CN103038355B (ja) |
AU (1) | AU2010355794B2 (ja) |
BR (1) | BR112012033087A2 (ja) |
CA (1) | CA2803264A1 (ja) |
CY (1) | CY1118701T1 (ja) |
DK (1) | DK2586869T3 (ja) |
ES (1) | ES2613580T3 (ja) |
HR (1) | HRP20170252T1 (ja) |
HU (1) | HUE031914T2 (ja) |
LT (1) | LT2586869T (ja) |
MX (1) | MX340672B (ja) |
NZ (1) | NZ606131A (ja) |
PL (1) | PL2586869T3 (ja) |
PT (1) | PT2586869T (ja) |
SI (1) | SI2586869T1 (ja) |
WO (1) | WO2011161274A1 (ja) |
ZA (1) | ZA201300632B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2464416B1 (es) | 2012-10-30 | 2015-03-31 | Biosinkco2 Tech Lda | Proceso para la producción de biomasa y productos derivados de ella mediante cultivo de algas unicelulares en medio acuoso alimentado con una corriente de CO2, y planta diseñada para tal fin |
KR101693549B1 (ko) * | 2014-07-10 | 2017-01-06 | 순천대학교 산학협력단 | 테트라셀미스 수에시카 분획물을 포함하는 비만의 예방 또는 치료용 조성물 |
WO2016150936A1 (en) | 2015-03-26 | 2016-09-29 | Tiberio Bruzzese | Purified compositions of polyunsaturated fatty acids, their preparation method and their use |
KR101693548B1 (ko) * | 2016-03-21 | 2017-01-06 | 순천대학교 산학협력단 | 테트라셀미스 수에시카 분획물을 포함하는 당뇨병의 예방 또는 치료용 조성물 |
CN109022508B (zh) * | 2018-08-24 | 2021-03-19 | 暨南大学 | 一种利用真眼点藻纲微藻生产棕榈油酸的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05503425A (ja) * | 1990-02-13 | 1993-06-10 | マーテック・バイオサイエンスィズ・コーポレイション | ドコサヘキサエン酸含有油の製造法 |
JPH0751051A (ja) * | 1993-08-17 | 1995-02-28 | Chikyu Kankyo Sangyo Gijutsu Kenkyu Kiko | 新規微細藻類及びそれを用いて高濃度二酸化炭素を固定する方法 |
WO2008134836A2 (en) * | 2007-05-02 | 2008-11-13 | Ouro Fino Participações E Empreendimentos S.A. | Process to produce biodiesel and/or fuel oil |
WO2009058799A1 (en) * | 2007-11-01 | 2009-05-07 | Wake Forest University School Of Medicine | Compositions and methods for prevention and treatment of mammalian diseases |
EP2135939A1 (en) * | 2008-06-20 | 2009-12-23 | Stroïazzo-Mougin, Bernard A. J. | Process for obtaining a high nutritional value product and/or for transforming it into energy resources |
-
2010
- 2010-06-23 HU HUE10737087A patent/HUE031914T2/en unknown
- 2010-06-23 PT PT107370876T patent/PT2586869T/pt unknown
- 2010-06-23 MX MX2012015207A patent/MX340672B/es active IP Right Grant
- 2010-06-23 ES ES10737087.6T patent/ES2613580T3/es active Active
- 2010-06-23 CA CA2803264A patent/CA2803264A1/en not_active Abandoned
- 2010-06-23 EP EP10737087.6A patent/EP2586869B1/en active Active
- 2010-06-23 PL PL10737087T patent/PL2586869T3/pl unknown
- 2010-06-23 JP JP2013515932A patent/JP5934704B2/ja not_active Expired - Fee Related
- 2010-06-23 BR BR112012033087A patent/BR112012033087A2/pt not_active IP Right Cessation
- 2010-06-23 US US13/805,421 patent/US9573875B2/en active Active
- 2010-06-23 CN CN201080067668.8A patent/CN103038355B/zh not_active Expired - Fee Related
- 2010-06-23 WO PCT/ES2010/070424 patent/WO2011161274A1/es active Application Filing
- 2010-06-23 LT LTEP10737087.6T patent/LT2586869T/lt unknown
- 2010-06-23 SI SI201031403A patent/SI2586869T1/sl unknown
- 2010-06-23 NZ NZ606131A patent/NZ606131A/en not_active IP Right Cessation
- 2010-06-23 DK DK10737087.6T patent/DK2586869T3/en active
- 2010-06-23 AU AU2010355794A patent/AU2010355794B2/en not_active Ceased
-
2013
- 2013-01-23 ZA ZA2013/00632A patent/ZA201300632B/en unknown
-
2017
- 2017-02-02 CY CY20171100150T patent/CY1118701T1/el unknown
- 2017-02-15 HR HRP20170252TT patent/HRP20170252T1/hr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05503425A (ja) * | 1990-02-13 | 1993-06-10 | マーテック・バイオサイエンスィズ・コーポレイション | ドコサヘキサエン酸含有油の製造法 |
JPH0751051A (ja) * | 1993-08-17 | 1995-02-28 | Chikyu Kankyo Sangyo Gijutsu Kenkyu Kiko | 新規微細藻類及びそれを用いて高濃度二酸化炭素を固定する方法 |
WO2008134836A2 (en) * | 2007-05-02 | 2008-11-13 | Ouro Fino Participações E Empreendimentos S.A. | Process to produce biodiesel and/or fuel oil |
WO2009058799A1 (en) * | 2007-11-01 | 2009-05-07 | Wake Forest University School Of Medicine | Compositions and methods for prevention and treatment of mammalian diseases |
EP2135939A1 (en) * | 2008-06-20 | 2009-12-23 | Stroïazzo-Mougin, Bernard A. J. | Process for obtaining a high nutritional value product and/or for transforming it into energy resources |
Non-Patent Citations (3)
Title |
---|
JPN6014044917; Renewable Energy Vol. 35, 201002, P. 1956-1966 * |
JPN6014044919; Biotechnol. Bioeng. Vol. 93, No. 3, 200511, P. 465-475 * |
JPN6014044921; Microbiol. Res. Vol. 163, No. 4, 200704, P. 373-379 * |
Also Published As
Publication number | Publication date |
---|---|
PL2586869T3 (pl) | 2017-05-31 |
ZA201300632B (en) | 2013-09-25 |
WO2011161274A1 (es) | 2011-12-29 |
CN103038355B (zh) | 2015-05-20 |
SI2586869T1 (sl) | 2017-04-26 |
MX2012015207A (es) | 2013-05-20 |
CY1118701T1 (el) | 2017-07-12 |
AU2010355794A1 (en) | 2013-02-07 |
BR112012033087A2 (pt) | 2019-09-24 |
ES2613580T3 (es) | 2017-05-24 |
HUE031914T2 (en) | 2017-08-28 |
LT2586869T (lt) | 2017-03-10 |
EP2586869B1 (en) | 2016-11-16 |
JP5934704B2 (ja) | 2016-06-15 |
DK2586869T3 (en) | 2017-02-20 |
PT2586869T (pt) | 2017-02-22 |
MX340672B (es) | 2016-07-20 |
CA2803264A1 (en) | 2011-12-29 |
HRP20170252T1 (hr) | 2017-04-07 |
US20130197086A1 (en) | 2013-08-01 |
US9573875B2 (en) | 2017-02-21 |
EP2586869A1 (en) | 2013-05-01 |
RU2013102897A (ru) | 2014-07-27 |
NZ606131A (en) | 2015-02-27 |
AU2010355794B2 (en) | 2015-10-29 |
CN103038355A (zh) | 2013-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014202880B2 (en) | Production and purification of esters of polyunsaturated fatty acids | |
US6846942B2 (en) | Method for preparing pure EPA and pure DHA | |
US8603488B2 (en) | Photoautotrophic growth of microalgae for omega-3 fatty acid production | |
KR100504324B1 (ko) | 도코사펜타엔산 함유물질의 이용 | |
JP5934704B2 (ja) | 所望の薬学的及び栄養学的脂肪酸を取得する方法 | |
WO1996033263A1 (fr) | Nouveaux micro-organismes capables de produire des acides gras hautement insatures et procede de production d'acides gras hautement insatures utilisant ces micro-organismes | |
WO2011092299A1 (fr) | Composition huileuse riche en monoglycerides de dha | |
JP7259034B2 (ja) | 超長鎖脂肪酸組成物 | |
EP3956283A1 (de) | Verfahren zur herstellung von polyolbasierten estern von acylverkappten 3-hydroxycarbonsäuren | |
US20110033595A1 (en) | Fatty acid fractionation process, fatty acid products and use thereof | |
KR101204748B1 (ko) | 고도 불포화 지방산을 고농도로 함유하는 트리글리세라이드 유지의 제조방법 | |
US10190075B2 (en) | Enrichment of palmitoleic acid and palmitoleic acid derivatives by dry and solvent-aided winterization | |
CN111635308B (zh) | 从山桐子籽油中联产制备亚油酸和a-亚麻酸的方法 | |
JP6806339B2 (ja) | 新規なトリグリセリド及びその用途 | |
RU2575107C2 (ru) | Способ получения жирных кислот фармакологического и пищевого назначения | |
WO2011067666A1 (en) | Processes to generate compositions of enriched fatty acids | |
EP3880649B1 (de) | Verfahren zur herstellung von polyolbasierten estern von hydroxycarbonsäuren | |
WO2020249197A1 (de) | Verfahren zur herstellung von acylverkappten 3-hydroxycarbonsäuren sowie deren salzen und estern | |
EP3880650B1 (de) | Verfahren zur herstellung von struktureinheiten auf basis von glyceriden von hydroxycarbonsäuren enthaltenden lipiden | |
EP4149992B1 (de) | Verfahren zur herstellung von mit polycarbonsäuren vernetzten polyglycerinestern der 3-hydroxybuttersäure | |
FR2839887A1 (fr) | Nouvelles compositions nutraceutiques et pharmaceutiques et leurs utilisations | |
NO20220910A1 (en) | Cetoleic acid composition | |
AU2022381752A1 (en) | Ketone precursors and methods therefor | |
JP2005087194A (ja) | 微生物を用いた共役高度不飽和脂肪酸含有培養物および共役高度不飽和脂肪酸含有油脂の製造方法 | |
JP2007230912A (ja) | 神経再生促進剤、および該促進剤を含む機能性食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141028 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160412 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160509 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5934704 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |